Search

The integration of deep learning into clinical decision infrastructure represents a pivotal advancement in healthcare systems and analytics, transforming disparate data streams into actionable intelligence that supports real-time, evidence-based decision-making. This narrative review synthesizes peer-reviewed literature to examine the systems-oriented implications of deep learning deployment within healthcare ecosystems. We focus on the architectural interplay among data ingestion, model inference, and decision-support loops, emphasizing how these elements enable closed-loop systems that adapt to evolving clinical contexts.Deep learning’s capacity to process multimodal data—encompassing electronic health records (EHRs), medical imaging, and real-time monitoring—has enabled sophisticated analytics frameworks that enhance diagnostic accuracy, prognostic modeling, and therapeutic optimization. For instance, fusion techniques combining imaging with structured EHR data have demonstrated potential for precision health applications, enabling nuanced patient stratification and personalized interventions. In mental health, deep learning models applied to outcome research have revealed patterns in longitudinal data, informing system-wide analytics that bridge predictive modeling with clinical workflows.From a systems perspective, the review highlights the evolution of clinical decision support systems (CDSS) augmented by deep learning, which incorporate feedback mechanisms to refine model performance and mitigate risks such as bias amplification. Ethical considerations, including algorithmic fairness and transparency, are integral to sustainable integration, as underscored by guidelines for early-stage evaluation and reporting standards. We explore architectures that facilitate human-AI collaboration, where deep learning serves as an augmentative tool rather than a replacement, ensuring alignment with clinical governance.Challenges in scalability, such as interoperability across healthcare infrastructures and the need for reproducible machine learning pipelines, are critically analyzed through a lens of systems resilience. The synthesis reveals opportunities for closed-loop systems that iteratively learn from interventions, promoting adaptive healthcare delivery. Ultimately, this review posits that deep learning’s role in clinical decision infrastructure hinges on holistic systems design that balances technological innovation with clinical utility and equity. By providing an original interpretive framework, we delineate pathways for integrating deep learning into healthcare analytics and advocate for governance models that prioritize patient-centered outcomes.

Breast cancer remains a leading cause of cancer-related mortality among women worldwide, underscoring the importance of effective screening strategies for early detection and improved survival. Although conventional modalities such as mammography reduce mortality, they are limited by false positives, false negatives, and overdiagnosis, particularly in dense breast tissue and diverse populations. Deep learning, especially convolutional neural networks (CNNs), has shown promise in improving diagnostic accuracy and reducing inter-reader variability; however, its translation into routine clinical practice requires critical evaluation beyond reported performance metrics. This critical review evaluates CNN-based deep learning applications for breast cancer detection across mammography, ultrasound, and MRI, with emphasis on training strategies and barriers to clinical deployment. A targeted literature search identified peer-reviewed studies focusing on CNN architectures, transfer learning, and implementation challenges. Findings indicate that models such as ResNet, DenseNet, and EfficientNet perform well in controlled settings, supported by transfer learning and data augmentation approaches. However, these results often fail to translate into consistent clinical performance, particularly across imaging modalities and real-world workflows. Limitations including demographic bias, insufficient external validation, and weak evidence of outcome or cost-effectiveness highlight a substantial gap between experimental success and clinical readiness. The review concludes that while deep learning in breast imaging is promising, its adoption should remain cautious and evidence-driven until robust clinical benefit is clearly demonstrated.

Oncology drug development is an expensive and high-failure process, with costs exceeding two billion dollars per approved drug and success rates below 10%. Deep learning has recently been explored as a strategy to improve efficiency across the drug discovery pipeline. This systematic review evaluates its application in target identification, compound screening and de novo drug design, and clinical trial optimization. Following PRISMA 2020 guidelines, multiple databases were searched and studies were screened using predefined inclusion criteria, with risk of bias assessed via established tools. The literature shows that graph neural networks and transformer-based models are the most widely used architectures, particularly in early-stage discovery tasks. Although many studies report strong in silico performance, often with AUC values above 0.80, only a small proportion demonstrate experimental or clinical validation. Overall, deep learning significantly advances computational drug discovery in oncology, but translation into clinically validated therapies remains limited, especially in trial optimization, highlighting the need for stronger prospective and experimental validation frameworks.

Sleep disorders, including obstructive sleep apnea, insomnia, restless legs syndrome, narcolepsy, and central sleep apnea, represent a major public health burden. Polysomnography is the diagnostic gold standard but is resource-intensive, leading to increasing use of home sleep apnea testing and wearable devices to improve accessibility. This systematic review evaluates deep learning models in sleep medicine across polysomnography, home sleep apnea testing, and wearable data, focusing on architectures, signal types, validation approaches, diagnostic tasks, and clinical readiness. A PRISMA 2020–compliant search was conducted in PubMed, IEEE Xplore, Scopus, and Web of Science for studies published from 2017 to 2025, including those applying deep learning for sleep staging, apnea/hypopnea detection, or sleep disorder diagnosis using PSG, HSAT, or wearable-derived signals. Twenty-nine studies were included. Convolutional neural networks were the most widely used architecture, often combined with recurrent or hybrid models for temporal dependencies, while transformer-based models have recently emerged for long-sequence sleep analysis. Deep learning methods demonstrate strong performance in sleep staging and respiratory event detection, especially using polysomnography data. However, limited external validation, heterogeneous datasets, and a lack of prospective clinical deployment remain major barriers to clinical translation.

Rare pediatric tumors like sarcomas, neuroblastoma, medulloblastoma, and retinoblastoma pose a challenge for developing deep learning models due to the limited availability of histopathology images, which are distributed across multiple institutions. This scarcity is compounded by privacy concerns, as whole-slide images often contain sensitive clinical and genomic data, and generative adversarial networks (GANs) risk memorizing and leaking training samples. To address this, a differentially private GAN framework is proposed for synthesizing high-resolution histopathology patches of rare pediatric cancers. The framework incorporates a generator for image synthesis, a discriminator for realism assessment, per-sample gradient clipping, Gaussian noise injection, and a privacy accountant, ensuring provable privacy guarantees during the training process. The synthetic images generated can aid in data augmentation, model pre-training, and benchmarking without exposing identifiable pathology data, offering a privacy-preserving solution for dataset augmentation while emphasizing the importance of clinical validation.

Anticoagulation management requires balancing multiple factors such as bleeding risk, thromboembolic risk, drug interactions, and renal function. Deep learning can assist in risk prediction, but its effectiveness relies on clinicians' ability to understand and verify the recommendations. Black-box models may recommend actions without providing clear explanations. In contrast, clinical guidelines are rule-based but not directly executable by neural models. This article introduces a neuro-symbolic XAI framework that combines deep learning predictions with explicit clinical guidelines. It includes a neural prediction module, a symbolic reasoning engine, and an integration layer for traceable justifications. The neuro-symbolic approach connects data-driven predictions to clinical rules, improving auditability and trustworthiness in decision support. This framework aims to enhance anticoagulation management by providing verifiable, clinician-understandable decision support, focusing on explainability-by-design.

Clinical notes, problem lists, medication orders, and billing codes are core components of the electronic health record. When these components conflict, the record may become less reliable for care delivery, quality measurement, and reimbursement. Current inconsistency detection is largely manual, episodic, and dependent on documentation audits. This approach is difficult to scale across encounters, specialties, and longitudinal records. This article proposes a deep learning NLP model for detecting contradictions among clinical notes, problem lists, medication orders, and billing codes. The goal is to support continuous documentation integrity surveillance. The proposed model uses transformer-based encoders for clinical text and embedding layers for structured coded fields. Cross-attention mechanisms align concepts across EHR modules before classifying consistency relationships. Conceptually, the model could surface discrepancies such as a diagnosis documented in a note but absent from the problem list, or a billing code unsupported by physician documentation. Its output would include an inconsistency category and an interpretable explanation for clinician review. A unified NLP model for cross-module inconsistency detection could improve EHR trustworthiness, documentation quality, and clinical audit workflows. Such a system should be evaluated prospectively before operational deployment.

Documentation burden is a leading contributor to physician burnout, yet detection often depends on periodic self-report surveys. Electronic health record audit logs provide an objective and continuous record of clinical work patterns that may reveal burden before physicians formally report distress. Moving from reactive survey assessment to proactive detection requires transforming complex, high-dimensional audit log signals into meaningful burden classifications. These signals must be modeled in a way that reflects workload intensity, temporal accumulation, and the interaction of documentation, inbox, and order-entry demands. This article proposes a conceptual deep neural network model for detecting physicians with high documentation burden. The model uses note length, time in the electronic health record, after-hours charting activity, inbox volume, and order entry patterns as core input domains. The proposed model uses a multi-input neural architecture that fuses aggregated and temporally aware features derived from raw electronic health record audit logs. The model would generate a burden probability score for each physician over a defined weekly period without requiring direct linkage to individual patient content. Conceptually, the model could identify physicians with rising documentation burden earlier than survey-based approaches. It would also be expected to reveal the dominant burden component, such as excessive inbox work, prolonged after-hours charting, unusually long notes, or high-complexity order entry. A deep learning model for documentation burden detection could help health systems move from burnout treatment to prevention. By connecting objective workload signals to targeted operational interventions, such a model could support physician well-being while preserving privacy and professional trust.

Clinical service line margins are increasingly pressured by value-based reimbursement, payer-specific contracting, and operational constraints that alter the relationship between clinical activity and financial performance. Traditional forecasting remains largely anchored in static budgets and delayed variance reports rather than continuously updated clinical and operational signals. Current financial planning tools often cannot dynamically incorporate evolving case mix, payer contracts, length of stay, resource consumption, and throughput patterns before deviations appear in the general ledger. As a result, service line leaders may recognize margin deterioration only after financial corrective action is already delayed. This article proposes a deep learning model for predicting clinical service line financial performance, including revenue, cost, and contribution margin. The model is designed to integrate clinical, operational, resource utilization, payer, and volume-based predictors into a unified forecasting framework. The proposed approach uses a temporal deep learning architecture that fuses static service line characteristics with dynamic monthly features. It would generate forward-looking financial forecasts with uncertainty-aware outputs and interpretable drivers for service line executives. Conceptually, the model would identify a pending margin shortfall driven by a combination of rising patient acuity, unfavorable payer contract exposure, higher resource consumption, longer length of stay, and declining procedure volume. Such forecasts would support earlier operational review and targeted cost-management actions before formal budget variance escalation. A deep learning model for service line financial forecasting could enable continuous surveillance of revenue, expense, and margin risk. By linking clinical activity, payer dynamics, and operational throughput, the approach could support proactive decision-making by service line directors and health system finance leaders.